More NewsRead More
RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy
October 20, 2014
RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging
September 30, 2014
RegeneRx Receives $1 Million Pursuant to Product License and Stock Purchase Agreement
September 03, 2014
New Report: Thymosin ?4 Prevents Heart Rupture & Improves Cardiac Function after Heart Attack in Mice
July 15, 2014
RegeneRx’s Strategic Partner G-treeBNT Preparing for Phase III Dry Eye Trials in Asia with RGN-259
July 07, 2014
Chinese FDA Accepts Phase 2 IND for RGN-259 for Dry Eye
June 23, 2014
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here